[go: up one dir, main page]

ATE536372T1 - Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung - Google Patents

Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung

Info

Publication number
ATE536372T1
ATE536372T1 AT99967350T AT99967350T ATE536372T1 AT E536372 T1 ATE536372 T1 AT E536372T1 AT 99967350 T AT99967350 T AT 99967350T AT 99967350 T AT99967350 T AT 99967350T AT E536372 T1 ATE536372 T1 AT E536372T1
Authority
AT
Austria
Prior art keywords
purification
lymphotoxin
immunolobulin
fusion proteins
active form
Prior art date
Application number
AT99967350T
Other languages
English (en)
Inventor
Jeffrey Browning
Konrad Miatkowski
Werner Meier
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536372(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE536372T1 publication Critical patent/ATE536372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT99967350T 1998-12-17 1999-12-16 Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung ATE536372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17
PCT/US1999/029873 WO2000036092A2 (en) 1998-12-17 1999-12-16 METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (1)

Publication Number Publication Date
ATE536372T1 true ATE536372T1 (de) 2011-12-15

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967350T ATE536372T1 (de) 1998-12-17 1999-12-16 Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung

Country Status (27)

Country Link
US (3) US7585946B2 (de)
EP (3) EP1141248B1 (de)
JP (4) JP4878676B2 (de)
KR (3) KR100732934B1 (de)
CN (2) CN101289512A (de)
AT (1) ATE536372T1 (de)
AU (2) AU777232B2 (de)
BR (1) BR9916325B1 (de)
CA (1) CA2354539A1 (de)
CY (1) CY1117003T1 (de)
CZ (1) CZ20012156A3 (de)
DK (2) DK1141248T3 (de)
EA (1) EA005270B1 (de)
EE (1) EE200100324A (de)
ES (1) ES2554482T5 (de)
HK (2) HK1038244A1 (de)
HU (1) HUP0200064A2 (de)
IL (3) IL143670A0 (de)
IS (1) IS5959A (de)
NO (1) NO20012991L (de)
NZ (3) NZ529276A (de)
PT (1) PT2374872E (de)
SG (1) SG123531A1 (de)
SI (1) SI2374872T2 (de)
SK (1) SK8552001A3 (de)
TR (2) TR200504220T2 (de)
WO (1) WO2000036092A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
BR9915025A (pt) * 1998-10-09 2001-08-14 Biogen Inc Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU5744501A (en) 2000-04-28 2001-11-12 Planet Biotechnology Inc Novel immunoadhesin for the prevention of rhinovirus infection
CA2434802C (en) * 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP2006515750A (ja) * 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
US20070099266A1 (en) * 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
WO2007115230A2 (en) * 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
KR20090078349A (ko) * 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2008049053A2 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
JP5431171B2 (ja) * 2007-03-15 2014-03-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 自己免疫障害の処置
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20110129468A1 (en) * 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2753634B1 (de) 2011-08-17 2017-11-01 Ares Trading S.A. Verfahren zur herstellung einer aktiven form des tnfr-fc-fusionsproteins
EP2906683B1 (de) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Säugerzellkulturverfahren zur proteinproduktion
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CN114853903A (zh) 2015-06-30 2022-08-05 桑福德伯纳姆普利斯医学发现研究所 Btla融合蛋白激动剂及其用途
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
EP0480923B1 (de) 1989-07-04 1993-09-29 Novo Nordisk A/S Verfahren zur herstellung von proteinen mit fviii aktivität und/oder fviii derivate
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
CA2086264C (en) * 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
EE05213B1 (et) 1996-10-25 2009-10-15 Biogen, Incorporated Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
JP2001502912A (ja) * 1996-10-30 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子レセプター―ライク２
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6693181B2 (en) * 1998-04-16 2004-02-17 Genentech, Inc. Protein secretion
ES2255765T3 (es) 1998-05-29 2006-07-01 Genentech, Inc. Procedimiento de cultivo de celulas para la produccion de glicoproteinas.
BR9915025A (pt) * 1998-10-09 2001-08-14 Biogen Inc Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
HK1223398A1 (zh) 2017-07-28
EE200100324A (et) 2002-10-15
BR9916325A (pt) 2001-10-02
US20100136625A1 (en) 2010-06-03
EP2374872B2 (de) 2019-02-20
DK2374872T3 (en) 2015-12-14
AU777232B2 (en) 2004-10-07
CN101289512A (zh) 2008-10-22
HK1038244A1 (en) 2002-03-08
JP4878676B2 (ja) 2012-02-15
DK2374872T4 (en) 2019-04-23
KR100732934B1 (ko) 2007-06-29
SI2374872T2 (sl) 2019-05-31
AU2005200042B2 (en) 2008-05-01
KR20060084860A (ko) 2006-07-25
PT2374872E (pt) 2015-12-09
JP5777171B2 (ja) 2015-09-09
US20130196376A1 (en) 2013-08-01
EA200100670A1 (ru) 2001-12-24
JP2010158252A (ja) 2010-07-22
NZ538599A (en) 2007-11-30
CY1117003T1 (el) 2017-04-05
KR20070091227A (ko) 2007-09-07
JP2014239697A (ja) 2014-12-25
IS5959A (is) 2001-05-31
JP2013116118A (ja) 2013-06-13
IL205698A (en) 2015-11-30
IL143670A0 (en) 2002-04-21
EP2374872A2 (de) 2011-10-12
SK8552001A3 (en) 2001-12-03
US7585946B2 (en) 2009-09-08
EP2374872A3 (de) 2011-10-19
EP1141248B1 (de) 2011-12-07
CN100387708C (zh) 2008-05-14
EP2374872B1 (de) 2015-11-25
ES2554482T5 (es) 2019-07-18
AU2005200042A1 (en) 2005-02-03
TR200504220T2 (tr) 2007-04-24
PL348816A1 (en) 2002-06-17
WO2000036092A2 (en) 2000-06-22
ES2554482T3 (es) 2015-12-21
TR200101703T2 (tr) 2002-05-21
SG123531A1 (en) 2006-07-26
CZ20012156A3 (cs) 2001-09-12
NZ549623A (en) 2008-05-30
AU2364400A (en) 2000-07-03
CN1333819A (zh) 2002-01-30
NO20012991D0 (no) 2001-06-15
BR9916325B1 (pt) 2011-06-28
EA005270B1 (ru) 2004-12-30
CA2354539A1 (en) 2000-06-22
IL229738A0 (en) 2014-01-30
US8709759B2 (en) 2014-04-29
NZ529276A (en) 2005-03-24
US20020039580A1 (en) 2002-04-04
WO2000036092A3 (en) 2000-11-23
KR20020013482A (ko) 2002-02-20
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
HUP0200064A2 (en) 2002-05-29
US8283138B2 (en) 2012-10-09
EP1141248A2 (de) 2001-10-10
EP3006563A1 (de) 2016-04-13
WO2000036092A9 (en) 2002-08-22
DK1141248T3 (da) 2012-03-12
JP2003517277A (ja) 2003-05-27

Similar Documents

Publication Publication Date Title
ATE536372T1 (de) Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung
ATE508755T1 (de) Verfahren zur inaktivierung von biologischen schadstoffen mithilfe von photosensibilisatoren
DE60040259D1 (de) Knotensteuerungsvorrichtung, Knotenvorrichtung und Verfahren zur Einstellung von optischen Pfaden
DE69735295D1 (de) Verfahren zur Aufkonzentrierung von Antikörperlösungen
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
ATE454621T1 (de) Verfahren für hochempfindliche hochgeschwindigkeits-kapillar-elektrophorese
DE69633563D1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE397969T1 (de) Katalysator zur behandlung von schadstoff- enhaltenden gasen unter vorbeugung von kapillarer kondensation
DE69936553D1 (de) Verfahren zur Konzentrationsmessung von NOx
DE59702864D1 (de) Verfahren und anordnung zur automatischen optischen qualitätskontrolle von flachen, ebenen produkten
DE59913665D1 (de) Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
DE59808384D1 (de) Verfahren zur auswertung von fehlern von textilen flächengebilden
DE69836075D1 (de) Verfahren zur spaltung von fusionproteinen
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE59801891D1 (de) Verfahren zum thermischen behandeln von flüchtige, brennbare bestandteile enthaltendem material
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
ATE232685T1 (de) Verfahren und zusammensetzungen zur bekämpfung von biologischer verschmutzung unter verwendung von sulfaminsäuren
DE69938774D1 (de) Verfahren zur isolierung, amplifizierung und charakterisierung von dns
DE50005627D1 (de) Chromatographiematerial und verfahren unter verwendung desselben
DE69738323D1 (de) Verfahren zur verringerung der abbaubarkeit von futterprotein
DE59803134D1 (de) Verfahren zur bekämpfung von schadpilzen
DE68924650D1 (de) Verfahren zur reinigung von tenascin.
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein
DE59510344D1 (de) Verfahren zur Kontaktierung von Glaskohlenstoff-Elektroden